🔎 Trials Near Me

Beranda › Kanker Payudara › Florida › Plantation

Uji klinis Kanker Payudara di Plantation, FL

14 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Plantation (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Menerima pesertaFase 3
  • Miami Cancer Institute, Plantation
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06377852

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Menerima pesertaFase 3
  • Miami Cancer Institute at Plantation, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Menerima pesertaFase 3
  • Miami Cancer Institute at Plantation, Plantation
  • UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Menerima pesertaFase 3
  • University of Miami-SCCC-Plantation, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06072612

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Menerima pesertaFase 2
  • Miami Cancer Institute - Plantation (MCIP), Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04893109

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Menerima pesertaFase 3
  • UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Menerima pesertaFase 3
  • Miami Cancer Institute Plantation, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT05696626

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Menerima pesertaFase 3
  • BRCR Medical Center, Inc- Internal Medicine, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06757634

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Menerima pesertaFase 2
  • Miami Cancer Institute at Baptist Health, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Apr 2026 · NCT04468061

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Menerima pesertaFase 3
  • UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1
  • BRCR Global, Plantation
  • Florida Clinical Trials Group, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2026 · NCT07424547

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • BRCR global, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Apr 2026 · NCT05785741

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Menerima pesertaStudi observasional
  • Baptist Cancer Care - Plantation, Plantation
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06401421

Uji klinis Kanker Payudara di kota lain

Studi lain di Plantation

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.